TMDX vs UNH

Transmedics (TMDX) maintains a compelling long-term thesis driven by its market-leading Organ Care System (OCS) and strategic expansion into integrated organ logistics (NOCS). The Q1 2026 results confirmed robust +21.2% YoY revenue growth, and FY2026 guidance was reiterated, reflecting continued management confidence in the NOCS rollout. However, the Q1 EPS of $0.30 significantly missed consensus ...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...